NanoBiotechnology Group

We are interested in how antibody targeted imaging agents and drug delivery vehicles can improve clinical diagnosis and therapy.

One major challenge is how to attach targeting units in a site specific fashion without affecting antibody function.

In 2015 we expanded our pioneering Sortase bioconjugation work and introduced the concept of ‘BioClick’, combining enzymatic and chemical ligation (Alt K et al., Angew Chem Int Ed Engl 2015, Hagemeyer CE et al., Nat Protoc 2015).

In collaboration with Professor Frank Caruso at The University of Melbourne, we have developed activated platelet targeted novel thrombin sensitive nanocapsules loaded with potent clot busters that can provide fast and risk free treatment of myocardial infarction and stroke (Gunawan ST et al., Adv Mate 2015).